EXHIBIT A

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202 662 6000
FAX 202 662 6291
WWW COV COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

KURT G CALIA
TEL 202 662 5602
FAX 202 778 5602
KCALIA@COV COM

March 10, 2006

VIA E-MAIL and FIRST CLASS MAIL

Defense Counsel
Attached Service List

Re: In re: '318 Patent Infringement Litigation; Civil Action No. 05-356-KAJ (consolidated)

Dear Counsel:

The purpose of this letter is to follow-up on the parties' February 13, 2006 telephonic conference about discovery in this matter. To date, we have not received any additional information from the defendants, with the exception of a letter from Mylan's counsel which we received earlier this week (and to which we will respond under separate cover). We would appreciate responses from the remaining defendants as to the various issues we raised about defendants' document production efforts, detailed in my earlier correspondence from January and February.

While each defendant has different document requests served on Plaintiffs, there is a great deal of overlap, and so we will address production issues with respect to categories of documents rather than attempt a request-by-request recitation of Plaintiffs' positions with respect to each of the defendants' individual requests. To the extent that any defendant has a concern with respect to a particular request not covered by the points set forth below (which we endeavored to make as comprehensive as possible), please let us know.

Limitation to NDA/ANDA Products. As you will recall, during the February 13 call, it was suggested by defendants that the parties limit their respective production of documents to only documents that relate to the specific products that are the subject of Janssen's New Drug Application ("NDA") 21-169 and the defendants' Abbreviated New Drug Applications ("ANDAs"). You will recall that defendants raised this in the context of our correspondence in which Plaintiffs requested the production of documents related to other Alzheimer's treatment products (actual or proposed) and other products containing galantamine – requests to which each of the defendants objected as overly broad, among other objections. Plaintiffs are willing to agree to the limitation proposed by defendants. However, as we have made clear, we reserve our

right to introduce evidence of other products that relates to objective considerations of nonobviousness. Accordingly, Plaintiffs will produce documents related to the Reminyl®/Razadyne® product that is the subject of NDA 21-169 (subject to the other limitations set forth in this letter) and not to other products. To date, we have produced over 35,000 pages of responsive documents that relate to the Reminyl®/Razadyne® product and to the '318 patent, and we anticipate producing additional documents. We hope to complete our paper production by the end of March.

Exclusion of Galantamine Synthesis/Product Formulation. During the February 13 telephone conference, we also discussed the possibility of excluding from discovery information related to galantamine synthesis and product formulation as not relevant to the present dispute. Lynn Ulrich suggested that the parties exchange the Table of Contents for the NDA and ANDAs, respectively, and identify the portions of those respective filings that will not be produced consistent with this limitation. To that end, we have enclosed with this letter the Index for NDA 21-169, and we state that Plaintiffs will exclude from their production of this NDA Sections 3.4 and the entirety of Section 4, with the exception of Section 4.6.3 entitled "Draft Labeling." We request that defendants send us the indexes for their respective ANDAs and identify the sections that will not be produced in a manner consistent with this agreed-upon limitation.

Regulatory Documents. During our call, counsel for certain defendants raised questions concerning the scope of Plaintiffs' production of regulatory documents. Consistent with the position set forth above, we will produce NDA 21-169, as well as Janssen's Investigational New Drug application ("IND") 51,538, except as to any portions that relate to synthesis or formulation information, to the extent they exist. Plaintiffs will also produce any other documents provided to or received from FDA related to the NDA or IND, to the extent such documents exist and can be located by means of a reasonably diligent search. Plaintiffs will not, however, produce any documents related to efforts to obtain regulatory approval outside of the United States. Such information is not reasonably calculated to lead to the discovery of admissible evidence, and the production of it would be quite burdensome to Plaintiffs.

Foreign Patents/Licenses/Disputes. We have also been asked to produce documents related to Plaintiffs' foreign patents and patent applications, licenses regarding such patents and applications, and disputes related to them. Plaintiffs have produced and will produce non-privileged documents related to foreign counterparts to the '318 patent, as well as other documents related to the licensing of the '318 patent and any disputes related to that patent. Plaintiffs also agree to produce, to the extent not already produced, the pleadings in the Waldheim matter in Austria. But Plaintiffs believe that a production of documents beyond these document categories would be overly burdensome and not reasonably calculated to lead to the discovery of

admissible evidence in this case. We will look again to make sure that all such documents have been either produced or identified on a privilege log, as appropriate.

Marketing Information. Plaintiffs agree to produce the master marketing file for the Reminyl®/Razadyne® product – i.e., the official file that contains the marketing material for this product maintained by Janssen to address any inquiries from FDA, in the event that they were to arise. This amounts to a substantial amount of material – on the order of approximately 20-30 boxes' worth – and should contain all information that is reasonably calculated to lead to the discovery of admissible evidence in this case. Janssen also has voluminous files that contain information that could be fairly characterized as related to marketing (e.g., adverse event reports, case report forms, and voluminous raw clinical data). While we do not believe that these documents are relevant to this case, we are willing to make them available for inspection should defendants wish to look at them. Because the volume is extraordinary – on the order of 1200 boxes or more – we will make these materials available for inspection should the defendants be interested in reviewing this material.

Documents Relating to Physician Prescribing Factors. During our February 13 call, we identified this category of documents as related to the objective considerations of nonobviousness and reiterated our request that defendants produce responsive documents. Plaintiffs will produce documents located by means of a reasonably diligent search and expect defendants to do the same.

Bioequivalence Information. I raised the production of bioequivalence-related information by defendants during the February 13 call, as has been requested in Plaintiffs' document requests. Plaintiffs are willing to withdraw its demand for the production of such documents by defendants upon confirmation that you will not rely on any bioequivalence-related information at trial.

Miscellaneous Requests from Defendants. During our call, defendants raised a number of additional requests, to which we respond as follows:

- We will supplement our interrogatory answers identifying the applicable objective considerations of nonobviousness. In so doing, we are hampered by the lack of production of related information by defendants, but we will nevertheless provide a supplemental response at this time while reserving the right to supplement further once defendants have complied with their discovery obligations in this matter.

- We will also supplement our interrogatory answers concerning Plaintiffs' claim construction position.

- While we believe we already provided you with the Bates ranges for the documents produced from the Ladas & Perry files, we identify them again as: SYN RAZ 0000806-0004318; SYN RAZ 0015198-0018866; and, SYN RAZ 0024999-0025308.

- We believe that we have produced all non-privileged communications between Janssen and Dr. Bonnie Davis related to the document categories for which we have indicated we will produce responsive documents. If Plaintiffs identify additional such documents, we will produce them promptly.

- We are not entirely clear as to the nature of the request that we produce an "internal copy" of the file history. Nevertheless, we confirm that we have produced a copy of the file history as it currently exists in the files of Ladas & Perry.

- We have produced or will produce any non-privileged documents (or log on a privilege log any privileged documents) related to Janssen's listing of the '318 patent in the Orange Book that we can locate by means of a reasonably diligent search.

- You have asked that we produce Synaptech's SEC filings from 1986 to the present. Because Synaptech is not a publicly traded company, we do not have any documents to produce.

- Except as to documents created in relation to this litigation, we will produce or log on a privilege log documents related to any analyses of the '318 patent and to any analyses of whether the Reminyl®/Razadyne® product is covered by it to the extent they exist and can be located by means of a reasonably diligent search.

- To the extent they exist and can be located by means of a reasonably diligent search, we will produce any employment agreements that Dr. Bonnie Davis had at the time of the conception or reduction to practice of the invention.

If you have any questions or concerns, please do not hesitate to contact me.

Sincerely,

Kurt Calia clb

Kurt G. Calia

Enclosure (via e-mail only)

cc: Steven Balick, Esq. (via email only)

SERVICE LIST

By Electronic Mail:	By Electronic Mail:
William A. Rakoczy *(wrakoczy@rmmslegal.com)* Christine J. Siwik *(csiwik@rmmslegal.com)* Amy D. Brody *(abrody@rmmslegal.com)* Lara Monroe-Sampson *(lmonroe-sampson@rmmslegal.com)* **Rakoczy, Molino, Mazzochi, Siwik LLP** 6 West Hubbard Street, Suite 500 Chicago, IL 60610 312.527.2157/phone; 312.527.4205/fax	Mary B. Matterer *(mmatterer@morrisjames.com)* **Morris James Hitchens & Williams LLP** 222 Delaware Avenue 10th Floor P.O. Box 2306 Wilmington, DE 19899-2306 302.888.6800/phone; 302.571.1750/fax
Counsel for Defendants Mylan Pharmaceuticals Inc. & Mylan Laboratories Inc.	

By Electronic Mail and First Class Mail:	By Electronic Mail:
Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson@kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **Kirkland & Ellis LLP** 655 Fifteenth Street, NW Suite 1200 Washington, DC 20005-5793 202.879.5000/phone; 202.879.5200/fax	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* **Young Conaway Stargatt & Taylor LLP** The Brandywine Building 1000 West Street 17th Floor Wilmington, DE 19899-0391 302.571.6600/phone; 302.571.1253/fax
Counsel for Defendants Teva Pharmaceuticals USA, Inc. & Teva Pharmaceuticals Industries Ltd.	

Taras A. Gracey *(tgracey@winston.com)* Lynn M. Ulrich *(lulrich@winston.com)* Brian L. Franklin *(bfranklin@winston.com)* **Winston & Strawn LLP** 35 West Wacker Drive Chicago, IL 60601 312.558.5600/phone; 312.558.5700/fax	
Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.	

Barbara S. Wahl *(wahl.barbara@arentfox.com)* Richard J. Berman *(berman.richard@arentfox.com)* D. Jacques Smith *(smith.jacques@arentfox.com)* Janine A. Carlan *(carlan.janine@arentfox.com)* John K. Hsu *(hsu.john@arentfox.com)* **Arent Fox PLLC** 1050 Connecticut Avenue, NW Washington, DC 20036-5339 202.857.6000/phone; 202.857.6395/fax	Philip A. Rovner *(provner@potteranderson.com)* **Potter Anderson & Corroon LLP** 1313 N. Market Street Hercules Plaza, 6th Floor P.O. Box 951 Wilmington, DE 19899-0951 302.984.6000/phone; 302.658.1192/fax
Counsel for Defendants Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.	

Robert J. Gunther, Jr. *(robert.gunther@lw.com)* James P. Barabas *(james.barabas@lw.com)* **Latham & Watkins LLP** 885 Third Avenue, Suite 1000 New York, NY 10022-4834 212.906.1200/phone; 212.751.4864/fax	Richard D. Kirk *(rkirk@bayardfirm.com)* **The Bayard Firm** 222 Delaware Avenue, Suite 900 P.O. Box 25130 Wilmington, DE 19899 302.655.5000/phone; 302.658.6395/fax
Counsel for Defendants Purepac Pharmaceutical Co. & Alpharma, Inc.	

Stuart Sender *(ssender@budd-larner.com)* **Budd Larner, P.C.** 150 John F. Kennedy Parkway Short Hills, NJ 07078-0999 973.315.4462/phone; 973.379.7734/fax	Richard L. Horwitz David E. Moore **Potter Anderson & Corroon LLP** 1313 N. Market Street Hercules Plaza, 6th Floor P. O. Box 951 Wilmington, DE 19899 302.984.6000/phone; 302.658.1192/fax
Counsel for Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.	

Alan Bernstein *(abernstein@crbcp.com)* Mona Gupta *(mgupta@crbcp.com)* **Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.** 1635 Market Street, 11th floor Philadelphia, PA 19103-2212 215.567.2010/phone; 215.751.1142/fax	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **Richards, Layton & Finger, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19899 302.651.7700/phone; 302.651.7701/fax
Counsel for Defendant Alphapharm Pty Ltd.	

Steven J. Balick *(sbalick@ashby-geddes.com)* John G. Day *(jday@ashby-geddes.com)* **Ashby & Geddes** 222 Delaware Ave., 17th Floor P.O. Box 1150 Wilmington, DE 19899 302.654.1888/phone; 302.654.2067/fax	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P., and Synaptech, Inc.	

EXHIBIT B

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

6 WEST HUBBARD STREET
SUITE 500
CHICAGO, IL 60610
www.rmmslegal.com

312-527-2157 main phone
312-527-4205 main fax

Amy D. Brody

312.222.6344 telephone
312.222.6345 facsimile
abrody@rmmslegal.com

April 3, 2006

VIA Facsimile and E-mail

Kurt G. Calia, Esq.
COVINGTON & BURLING
1201 Pennsylvania Avenue, NW
Washington, D.C. 20004-2401

Re: ***In Re: '318 Patent Infringement Litigation***
C.A. No. 05-356 (KAJ) (D. Del.) (consolidated)

Dear Kurt:

As you know, Defendants have followed up numerous times over the course of the last several months requesting that Plaintiffs immediately produce, among others, documents concerning the marketing of galantamine, secondary considerations of non-obviousness and commercial success—documents that clearly are relevant to the pending issues in this litigation. Despite Defendants' endless efforts to obtain such information, to date, Plaintiffs have failed and/or refused to produce these and other categories of documents. You finally advised in your March 10 letter that Plaintiffs intend to produce the master marketing file for the Reminyl®/Razadyne® product, which amounts to approximately 20-30 boxes. Notwithstanding this "substantial amount of material," you then advised in that same letter that Plaintiffs planned to make available for inspection to Defendants another 1,200 boxes of marketing-related materials. Based on Plaintiffs' statements, Defendants fully expected that Plaintiffs would produce such documents within a short time frame, and/or that Plaintiffs would make such documents immediately available to Defendants for inspection.

Over three weeks have now passed, and Defendants are still left only with Plaintiffs' empty promise that the 20-30 boxes of documents "will be produced soon." It is now clear that Plaintiffs' actions in this connection were solely intended to mislead Defendants and procure more time for Plaintiffs to evade complying with their discovery obligations. These documents are highly relevant and likely critical to the narrowed issues that remain pending in this

litigation, which you have not denied. As such, Plaintiffs' continued failure to produce the documents or otherwise make the documents available for inspection is severely prejudicing Defendants' litigation efforts. We request that Plaintiffs immediately produce the 20-30 boxes of marketing-related documents that Plaintiffs have previously referenced, and by no later than the close of business, Wednesday, April 5, 2006. Moreover, please advise by that time when Defendants may inspect the 1,200 additional boxes of documents. Given the multiple requests for these documents and that more than six (6) months have passed since Defendants served their initial document requests on Plaintiffs seeking such documents, Plaintiffs have no excuse for further delay.

Moreover, we requested in our March 16, 2006 letter that Plaintiffs immediately produce certain documents from the files of Bonnie Davis, which were addressed during Dr. Davis' deposition conducted on February 8-9, 2006. Consistent with past conduct, Plaintiffs apparently have chosen to ignore this correspondence from Defendants as well. Again, we ask that all such documents referenced in our March 16 letter be produced immediately, and by no later than the close of business, Wednesday, April 5, 2006.

At this stage of discovery, if Plaintiffs fail to provide such documents, Defendants will have no choice but to present these matters to the Court for resolution. We look forward to hearing from you.

Very truly yours,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

Amy D. Brody

Amy D. Brody

cc: Attached service list

SERVICE LIST

Via Facsimile and E-mail:

George F. Pappas *(gpappas@cov.com)* Roderick R. McKelvie *(mckelvie@cov.com)* Christopher N. Sipes *(csipes@cov.com)* Jeffrey B. Elikan *(jelikan@cov.com)* Laura H. McNeill *(lmcneill@cov.com)* Kurt G. Calia *(kcalia@cov.com)* **COVINGTON & BURLING** 1201 Pennsylvania Avenue, N.W. Washington, D.C. 20004-2401 Telephone: (202) 662-6000 Facsimile: (202) 662-6291	John G. Day *(jday@ashby-geddes.com)* Steven J. Balick *(sbalick@ashby-geddes.com)* **ASHBY & GEDDES** 222 Delaware Ave., 17th Fl. P.O. Box 1150 Wilmington, DE 19899 Telephone: (302) 654-1888 Facsimile: (302) 654-2067
Steven P. Berman *(sberman@corus.jnj.com)* Office of General Counsel **JOHNSON & JOHNSON** One Johnson & Johnson Plaza New Brunswick, NJ 08933 Telephone: (732) 524-2805 Facsimile: (732) 524-5866	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P. and Synaptech, Inc.	

Via E-mail:

Alan Bernstein *(abernstein@crbcp.com)* (x124) Mona Gupta *(mgupta@crbcp.com)* (x160) **CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.** 1635 Market Street, 11th Floor Philadelphia, PA 19103-2212 Telephone: (215) 567-2010 Facsimile: (215) 751-1142	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **RICHARDS, LAYTON & FINGER, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19801 Telephone: (302) 651-7509 Facsimile: (302) 651-7701
Counsel for Defendant Alphapharm Pty Ltd.	

Daniel F. Attridge, P.C. *(dattridge@kirkland.com)* Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson@kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **KIRKLAND & ELLIS LLP** 655 Fifteenth Street, N.W., Suite 1200 Washington, D.C. 20005-5793 Telephone: (202) 879-5000 Facsimile: (202) 879-5200	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* Adam W. Poff *(apoff@ycst.com)* **YOUNG CONAWAY STARGATT & TAYLOR LLP** The Brandywine Building 1000 West St., 17th Floor P.O. Box 391 Wilmington, DE 19899-0391 Telephone: (302) 571-6600 Facsimile: (302) 571-1253
Counsel for Defendants Teva Pharmaceuticals USA and Teva Pharmaceuticals Industries Ltd.	

Mary B. Matterer *(mmatterer@morrisjames.com)* **MORRIS JAMES HITCHENS & WILLIAMS LLP** 222 Delaware Ave., 10th Floor P.O. Box 2306 Wilmington, DE 19899-2306 Telephone: (302) 888-6800 Facsimile: (302) 571-1750	
Counsel for Defendants Mylan Pharmaceuticals Inc. and Mylan Laboratories Inc.	

George C. Lombardi *(glombardi@winston.com)* Taras A. Gracey *(tgracey@winston.com)* Lynn M. Ulrich *(lulrich@winston.com)* Brian L. Franklin *(bfranklin@winston.com)* **WINSTON & STRAWN LLP** 35 West Wacker Dr. Chicago, IL 60601 Telephone: (312) 558-5000 Facsimile: (312) 558-5700	John C. Phillips, Jr. *(jcp@pgslaw.com)* Brian E. Farnan *(bef@pgslaw.com)* **PHILLIPS, GOLDMAN & SPENCE, P.A.** 1200 N. Broom St. Wilmington, DE 19806 Telephone: (302) 655-4200 Facsimile: (302) 655-4210
Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.	

Robert J. Gunther, Jr. *(robert.gunther@lw.com)* James P. Barabas *(james.barabas@lw.com)* **LATHAM & WATKINS LLP** 885 Third Ave., Suite 1000 New York, NY 10022-4802 Telephone: (212) 906-1200 Facsimile: (212) 751-4864	Richard D. Kirk *(rkirk@bayardfirm.com)* **THE BAYARD FIRM** 222 Delaware Ave., Suite 900 P.O. Box 25130 Wilmington, DE 19899 Telephone: (302) 655-5000 Facsimile: (302) 658-6395
Counsel for Defendants Purepac Pharmaceutical Co. and Alpharma Inc.	

Stuart Sender (*ssender@budd-larner.com*) **BUDD LARNER** 150 John F. Kennedy Parkway Short Hills, NY 07078-0999 Telephone: (973) 315-4462 Facsimile: (973) 379-7734	Richard L. Horwitz (rhorwitz@potteranderson.com) **POTTER ANDERSON & CORROON LLP** Hercules Plaza P.O. Box 951 Wilmington, DE 19899 Telephone: (302) 984-6027 Facsimile: (302) 658-1192
Counsel for Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.	

EXHIBIT C

From: Calia, Kurt [mailto:kcalia@cov.com]
Sent: Monday, May 15, 2006 3:16 PM
To: Amy D. Brody
Cc: William A. Rakoczy; Christine Siwik
Subject: RE: In re '318 Patent Infringement Litigation -- Documents

Amy

As you know, Plaintiffs first offered to make this material available for inspection to defendants on March 10, and today's is the first request we have received asking to review this material. When you last inquired as to the status of these documents on April 3, I responded on April 5 suggesting that because the logistics associated with these voluminous materials is complicated (which is the case both in terms of location and content -- some of the documents are likely privileged and/or contain patient-sensitive information, and they exist in multiple locations), and I suggested that the parties have a teleconference to discuss the mechanics of such an inspection. I did not hear back from you.

Nevertheless, we are prepared to discuss with this matter with you this week. In preparation for such a discussion, it would be important for us to know whether one defendant will conduct the review on behalf of all defendants, whether you anticipate inspecting documents at one location before moving to another location or whether you hope to inspect documents at multiple locations in parallel, and when you would be available to begin and how many people will be involved. Once we have this information, we will be in a position to confer with our client about how to make these materials available and what kinds of pre-review procedures are appropriate so as to safeguard privileged and patient-specific information.

We look forward to hearing from you.

Sincerely,
Kurt G. Calia
Covington & Burling
1201 Pennsylvania Ave., N.W.
Washington, D.C. 20004-2401
202.662.5602 (v); 202.778.5602 (f)
kcalia@cov.com; www.cov.com

From: Amy D. Brody [mailto:ABrody@rmmslegal.com]
Sent: Monday, May 15, 2006 3:07 PM
To: Calia, Kurt
Cc: William A. Rakoczy; Christine Siwik
Subject: In re '318 Patent Infringement Litigation -- Documents

Kurt:

As a follow up to our prior correspondence on this matter, it is my understanding that the approximate 1,200 boxes of documents Plaintiffs are making available for Defendants' review and inspection in this discovery are located in various locations. So

that Defendants may make appropriate arrangements to review these documents, could you please advise at what location(s) Plaintiffs intend to make the documents available for Defendants' review, and when Defendants may review those documents. Thanks much.

Regards,

Amy

Amy D. Brody
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
6 W. Hubbard Street, Suite 500
Chicago, IL 60610
Telephone: 312.222.6344
Facsimile: 312.222.6345
abrody@rmmslegal.com

EXHIBIT D

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

6 WEST HUBBARD STREET
SUITE 500
CHICAGO, IL 60610
www.rmmslegal.com

312-527-2157 main phone
312-527-4205 main fax

Amy D. Brody

312.222.6344 telephone
312.222.6345 facsimile
abrody@rmmslegal.com

June 12, 2006

VIA Facsimile and E-mail

Kurt G. Calia, Esq.
COVINGTON & BURLING
1201 Pennsylvania Avenue, NW
Washington, D.C. 20004-2401

Re: ***In Re: '318 Patent Infringement Litigation***
C.A. No. 05-356 (KAJ) (D. Del.) (consolidated)

Dear Kurt:

As you know, Plaintiffs first disclosed to Defendants in March that Plaintiffs had approximately 1,200 boxes of documents responsive to Defendants' discovery requests—requests that were served as early as September 2005. Since then, we have followed up multiple times concerning these documents. In an effort to facilitate Defendants' review and inspection, we have requested, among other things, that you advise as to the locations of the documents since you originally advised the documents were located in various locations. Plaintiffs have, however, failed to provide any substantive information about these documents, including information as straightforward as their location. Rather, you have responded with questions such as how many Defendants will conduct the review and where Defendants will conduct their review. Plaintiffs do not need this information in order to tell us where the documents are located. Quite plainly, Plaintiffs are just stalling.

Please give us a straight answer in response to the following: (a) where are these 1,200 boxes of documents located; and (b) if in multiple locations, (i) identify what types or categories of documents are at each particular location and (ii) the approximate number of boxes of documents at each particular location. Upon receiving this information, we can then advise you concerning Defendants' proposed review of the documents, including when and where we will begin such review. If we do not receive this information from you, Plaintiffs will have left us with no choice but to ask the Court to compel production of same. We sincerely hope, however, that Plaintiffs will not force us to waste the Court's time for such basic information.

We look forward to your prompt response.

Very truly yours,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

Amy D. Brody

Amy D. Brody

cc: Attached service list

SERVICE LIST

Via Facsimile and E-mail:

George F. Pappas *(gpappas@cov.com)* Roderick R. McKelvie *(mckelvie@cov.com)* Christopher N. Sipes *(csipes@cov.com)* Jeffrey B. Elikan *(jelikan@cov.com)* Laura H. McNeill *(lmcneill@cov.com)* **Kurt G. Calia** *(kcalia@cov.com)* **COVINGTON & BURLING** 1201 Pennsylvania Avenue, N.W. Washington, D.C. 20004-2401 Telephone: (202) 662-6000 Facsimile: (202) 662-6291	John G. Day *(jday@ashby-geddes.com)* **Steven J. Balick** *(sbalick@ashby-geddes.com)* **ASHBY & GEDDES** 222 Delaware Ave., 17th Fl. P.O. Box 1150 Wilmington, DE 19899 Telephone: (302) 654-1888 Facsimile: (302) 654-2067
Steven P. Berman *(sberman@corus.jnj.com)* Office of General Counsel **JOHNSON & JOHNSON** One Johnson & Johnson Plaza New Brunswick, NJ 08933 Telephone: (732) 524-2805 Facsimile: (732) 524-5866	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P. and Synaptech, Inc.	

Via E-mail:

Alan Bernstein *(abernstein@crbcp.com)* (x124) Mona Gupta *(mgupta@crbcp.com)* (x160) **CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.** 1635 Market Street, 11th Floor Philadelphia, PA 19103-2212 Telephone: (215) 567-2010 Facsimile: (215) 751-1142	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **RICHARDS, LAYTON & FINGER, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19801 Telephone: (302) 651-7509 Facsimile: (302) 651-7701
Counsel for Defendant Alphapharm Pty Ltd.	

Daniel F. Attridge, P.C. *(dattridge@kirkland.com)* Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson@kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **KIRKLAND & ELLIS LLP** 655 Fifteenth Street, N.W., Suite 1200 Washington, D.C. 20005-5793 Telephone: (202) 879-5000 Facsimile: (202) 879-5200	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* Adam W. Poff *(apoff@ycst.com)* **YOUNG CONAWAY STARGATT & TAYLOR LLP** The Brandywine Building 1000 West St., 17th Floor P.O. Box 391 Wilmington, DE 19899-0391 Telephone: (302) 571-6600 Facsimile: (302) 571-1253
Counsel for Defendants Teva Pharmaceuticals USA and Teva Pharmaceuticals Industries Ltd.	

Mary B. Matterer *(mmatterer@morrisjames.com)*
MORRIS JAMES HITCHENS & WILLIAMS LLP
222 Delaware Ave , 10th Floor
P.O. Box 2306
Wilmington, DE 19899-2306
Telephone: (302) 888-6800
Facsimile: (302) 571-1750

Counsel for Defendants Mylan Pharmaceuticals Inc. and Mylan Laboratories Inc.

George C. Lombardi *(glombardi@winston.com)*
Taras A. Gracey *(tgracey@winston.com)*
Lynn M. Ulrich *(lulrich@winston.com)*
Mustafa Hersi *(mhersi@winston.com)*
WINSTON & STRAWN LLP
35 West Wacker Dr.
Chicago, IL 60601
Telephone: (312) 558-5000
Facsimile: (312) 558-5700

John C. Phillips, Jr. *(jcp@pgslaw.com)*
Brian E. Farnan *(bef@pgslaw.com)*
PHILLIPS, GOLDMAN & SPENCE, P.A.
1200 N. Broom St.
Wilmington, DE 19806
Telephone: (302) 655-4200
Facsimile: (302) 655-4210

Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.

EXHIBIT E

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202 662 6000
FAX 202 662 6291
WWW COV COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

KURT G CALIA
TEL 202 662 5602
FAX 202 778 5602
KCALIA@COV COM

April 5, 2006

VIA E-MAIL and FIRST CLASS MAIL

Amy D. Brody, Esq.
Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard Street, Suite 500
Chicago, IL 60610

Re: In re: '318 Patent Infringement Litigation; Civil Action No. 05-356-KAJ (consolidated)

Dear Amy:

This is in response to your letter from Monday evening regarding Plaintiffs' document production in this matter. We are surprised by the tone and content of your letter given the parties' respective discovery efforts to date, and we otherwise respond as follows.

First, we have in fact produced the master marketing materials for Reminyl®/Razadyne® as I indicated that we intended to do by the end of March. On Friday, we produced over 17,000 pages of documents, which comprise the printed material from that master file, and we supplemented that production yesterday with a series of marketing-related videos, DVDs, and CDs.

Second, we produced yesterday Janssen NDA 21-169 and other publications and research-related information concerning galantamine, which comprises another 133,000 pages of documents, bringing Plaintiffs' total production to over 190,000 pages in this case. The production of this material took slightly longer than expected because we needed to redact patient-identifying information from the NDA in order to comply with HIPAA. *See* Pub. L. No. 104-191.

Third, we are in the process of reviewing for production Janssen's IND R113675, which we believe will comprise an additional and very substantial production, and which we hope to produce within the next several days (we are again reviewing it for patient-identifying information). And as you know, we have offered to make available for inspection still additional documents -- an offer that until receipt of your April 3 letter, defendants have ignored although I made it nearly a month ago.

As to the inspection of these materials, I suggest that we have a teleconference to discuss the mechanics, which are complicated by the fact that the boxes contain some information that is privileged and/or that is patient-sensitive information which raises similar concerns to those set forth above concerning our NDA and IND productions. Also, not all of the approximately 1,200 boxes of material are in the same location, and so we would need to coordinate on where the inspection should take place. Please let us know when you are available for such a discussion.

While we would not see fit to dictate how defendants conduct discovery in this case, we ask you to consider whether you wish to conduct this inspection before you have completed a review of the materials produced to date so that the parties do not expend resources unnecessarily.

Lastly, it is entirely inaccurate for you to state in the face of this substantial discovery effort that "Plaintiffs' actions in this connection [with earlier correspondence] were solely intended to mislead Defendants and procure more time for Plaintiffs to evade complying with discovery obligations." It is difficult to take seriously this statement from Mylan – which has produced a mere 7,100 pages of documents, has proved unable to present a Rule 30(b)(6) deposition witness within seven weeks' time, and has still refused to provide dates concerning deposition topics noticed on February 21. In any event, we ask that you refrain from such unproductive rhetoric in the future which does nothing to promote the resolution of discovery disputes.

Please let me know if you have any questions or concerns.

Sincerely,



Kurt G. Calia

cc: All defense counsel (via email; see attached service list)
Steven Balick, Esq. (via email)

SERVICE LIST

By Electronic Mail and First Class Mail:	By Electronic Mail:
William A. Rakoczy *(wrakoczy@rmmslegal.com)* Christine J. Siwik *(csiwik@rmmslegal.com)* Amy D. Brody *(abrody@rmmslegal.com)* Lara Monroe-Sampson *(lmonroe-sampson@rmmslegal.com)* **Rakoczy, Molino, Mazzochi, Siwik LLP** 6 West Hubbard Street, Suite 500 Chicago, IL 60610 312.527.2157/phone; 312.527.4205/fax	Mary B. Matterer *(mmatterer@morrisjames.com)* **Morris James Hitchens & Williams LLP** 222 Delaware Avenue 10th Floor P.O. Box 2306 Wilmington, DE 19899-2306 302.888.6800/phone; 302.571.1750/fax
Counsel for Defendants Mylan Pharmaceuticals Inc. & Mylan Laboratories Inc.	

By Electronic Mail and First Class Mail:	By Electronic Mail:
Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson @kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **Kirkland & Ellis LLP** 655 Fifteenth Street, NW Suite 1200 Washington, DC 20005-5793 202.879.5000/phone; 202.879.5200/fax	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* **Young Conaway Stargatt & Taylor LLP** The Brandywine Building 1000 West Street 17th Floor Wilmington, DE 19899-0391 302.571.6600/phone; 302.571.1253/fax
Counsel for Defendants Teva Pharmaceuticals USA, Inc. & Teva Pharmaceuticals Industries Ltd.	

Taras A. Gracey *(tgracey@winston.com)* Lynn M. Ulrich *(lulrich @winston.com)* Brian L. Franklin *(bfranklin@winston.com)* **Winston & Strawn LLP** 35 West Wacker Drive Chicago, IL 60601 312.558.5600/phone; 312.558.5700/fax	
Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.	

Barbara S. Wahl *(wahl.barbara@arentfox.com)* Richard J. Berman *(berman.richard@arentfox.com)* D. Jacques Smith *(smith.jacques@arentfox.com)* Janine A. Carlan *(carlan.janine@arentfox.com)* John K. Hsu *(hsu.john@arentfox.com)* **Arent Fox PLLC** 1050 Connecticut Avenue, NW Washington, DC 20036-5339 202.857.6000/phone; 202.857.6395/fax	Philip A. Rovner *(provner@potteranderson.com)* **Potter Anderson & Corroon LLP** 1313 N. Market Street Hercules Plaza, 6th Floor P.O. Box 951 Wilmington, DE 19899-0951 302.984.6000/phone; 302.658.1192/fax
Counsel for Defendants Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.	

Robert J. Gunther, Jr. *(robert.gunther@lw.com)* James P. Barabas *(james.barabas@lw.com)* **Latham & Watkins LLP** 885 Third Avenue, Suite 1000 New York, NY 10022-4834 212.906.1200/phone; 212.751.4864/fax	Richard D. Kirk *(rkirk@bayardfirm.com)* **The Bayard Firm** 222 Delaware Avenue, Suite 900 P.O. Box 25130 Wilmington, DE 19899 302.655.5000/phone; 302.658.6395/fax
Counsel for Defendants Purepac Pharmaceutical Co. & Alpharma, Inc.	

Stuart Sender *(ssender@budd-larner.com)* **Budd Larner, P.C.** 150 John F. Kennedy Parkway Short Hills, NJ 07078-0999 973.315.4462/phone; 973 379.7734/fax	Richard L. Horwitz David E. Moore **Potter Anderson & Corroon LLP** 1313 N Market Street Hercules Plaza, 6th Floor P. O. Box 951 Wilmington, DE 19899 302.984.6000/phone; 302.658.1192/fax
Counsel for Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.	

Alan Bernstein *(abernstein@crbcp.com)* Mona Gupta *(mgupta@crbcp.com)* **Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.** 1635 Market Street, 11th floor Philadelphia, PA 19103-2212 215.567.2010/phone; 215.751.1142/fax	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **Richards, Layton & Finger, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19899 302.651.7700/phone; 302.651.7701/fax
Counsel for Defendant Alphapharm Pty Ltd.	

Steven J. Balick *(sbalick@ashby-geddes.com)* John G. Day *(jday@ashby-geddes.com)* **Ashby & Geddes** 222 Delaware Ave., 17th Floor P.O. Box 1150 Wilmington, DE 19899 302.654.1888/phone; 302.654.2067/fax	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P., and Synaptech, Inc.	

EXHIBIT F

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202 662 6000
FAX 202 662 6291
WWW COV COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

KURT G CALIA
TEL 202 662 5602
FAX 202 778 5602
KCALIA@COV COM

June 12, 2006

VIA E-MAIL and FIRST CLASS MAIL

Christine J. Siwik, Esq.
Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard Street, Suite 500
Chicago, IL 60610

Re: In re: '318 Patent Infringement Litigation; Civil Action No. 05-356-KAJ (consolidated)

Dear Christine:

This is in response to your letter dated May 31, 2006 regarding the discovery in this case. The timing of defendants' document production and presentation of deposition witnesses (and, of course, the Court's orders regarding these subjects) are clearly set forth in the record, and we see little value in directing you to the relevant portions of that information to disprove the allegations of your letter.

We will take the time to address two points, namely, Mylan's counter-factual charge that Plaintiffs have delayed discovery because of third party discovery served in May and because of our document production. Mylan's position is entirely without merit.

First, while nearly one-half of your letter is dedicated to the alleged delay associated with third party discovery that Plaintiffs' noticed in May, it fails to identify any prejudice to defendants that has resulted (nor could it). There is nothing improper about Plaintiffs' conduct in this regard, and Plaintiffs intend to complete this discovery within the time limits established by the Court.

Second, you assert that Plaintiffs have delayed the production of documents in this case, and make the manifestly false charge that Plaintiffs have "repeatedly refused to make available 1,200 boxes of documents." As to the latter point, our correspondence on the availability of these documents for inspection is clear, as is defendants' conduct concerning them. You also claim that Plaintiffs have belatedly produced documents, although you fail to identify a single such document or the alleged effect on defendants that has resulted. Your bald allegations cannot change the record in this case. A balanced review of the record compels the conclusion set

forth in my May 26 letter – namely, that defendants are trying to run out the clock by delay at every turn, in contrast to Plaintiffs' discovery efforts. We reserve all right to bring defendants' dilatory conduct to the Court's attention.

Sincerely,

Kurt G. Calia

cc: All defense counsel (via email; see attached service list)
Steven Balick, Esq. (via email)

SERVICE LIST

By Electronic Mail and First Class Mail:	By Electronic Mail:
William A. Rakoczy *(wrakoczy@rmmslegal.com)* Christine J. Siwik *(csiwik@rmmslegal.com)* Amy D. Brody *(abrody@rmmslegal.com)* Lara Monroe-Sampson *(lmonroe-sampson@rmmslegal.com)* **Rakoczy, Molino, Mazzochi, Siwik LLP** 6 West Hubbard Street, Suite 500 Chicago, IL 60610 312.527.2157/phone; 312.527.4205/fax	Mary B. Matterer *(mmatterer@morrisjames.com)* **Morris James Hitchens & Williams LLP** 222 Delaware Avenue 10th Floor P.O. Box 2306 Wilmington, DE 19899-2306 302 888 6800/phone; 302 571.1750/fax
Counsel for Defendants Mylan Pharmaceuticals Inc. & Mylan Laboratories Inc.	

By Electronic Mail and First Class Mail:	By Electronic Mail:
Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson @kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **Kirkland & Ellis LLP** 655 Fifteenth Street, NW Suite 1200 Washington, DC 20005-5793 202.879.5000/phone; 202.879.5200/fax	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* **Young Conaway Stargatt & Taylor LLP** The Brandywine Building 1000 West Street 17th Floor Wilmington, DE 19899-0391 302.571.6600/phone; 302.571.1253/fax
Counsel for Defendants Teva Pharmaceuticals USA, Inc. & Teva Pharmaceuticals Industries Ltd.	

Taras A. Gracey *(tgracey@winston.com)* Lynn M. Ulrich *(lulrich @winston.com)* Brian L. Franklin *(bfranklin@winston.com)* **Winston & Strawn LLP** 35 West Wacker Drive Chicago, IL 60601 312.558.5600/phone; 312.558.5700/fax	
Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.	

Alan Bernstein *(abernstein@crbcp.com)* Mona Gupta *(mgupta@crbcp.com)* **Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.** 1635 Market Street, 11th floor Philadelphia, PA 19103-2212 215.567 2010/phone; 215.751.1142/fax	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **Richards, Layton & Finger, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19899 302.651.7700/phone; 302.651.7701/fax
Counsel for Defendant Alphapharm Pty Ltd.	

Steven J. Balick *(sbalick@ashby-geddes.com)* John G. Day *(jday@ashby-geddes.com)* **Ashby & Geddes** 222 Delaware Ave., 17th Floor P.O. Box 1150 Wilmington, DE 19899 302.654.1888/phone; 302.654.2067/fax	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P., and Synaptech, Inc.	

EXHIBIT G

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

6 WEST HUBBARD STREET
SUITE 500
CHICAGO, IL 60610
www.rmmslegal.com

312-527-2157 main phone
312-527-4205 main fax

Christine J. Siwik
312.222.6304 telephone
312.222.6324 facsimile
csiwik@rmmslegal.com

May 31, 2006

VIA Facsimile and E-mail

Kurt G. Calia
COVINGTON & BURLING
1201 Pennsylvania Avenue, NW
Washington, D.C. 20004-2401

Re: ***In Re: '318 Patent Infringement Litigation***
C.A. No. 05-356 (KAJ) (D. Del.) (consolidated)

Dear Kurt:

This responds to your May 26, 2006 letter.

To begin, it is ironic that we would receive a letter from you complaining about delays allegedly caused by Defendants on the same day that Plaintiffs demonstrate so convincingly how they have failed to carry out discovery in a timely manner. As you have asked us to "stick to the facts," which we always have done in any event, we offer the following undisputed facts.

On May 26, Plaintiffs sent out not one, but *five* third-party subpoenas. Each of those subpoenas seeks at least deposition testimony, if not a deposition and documents. Plaintiffs sent out another one yesterday, May 30, and of course issued yet another one back on May 22. Plaintiffs have no excuse for this delay. The notice letter attached to the IVAX subpoena is dated April 29, 2005; the notice letter attached to the Mutual subpoena is dated April 22, 2005; the notice letters attached to the Sandoz subpoena are dated May 11, 2005 and May 12, 2005; the notice letter attached to the Apotex subpoena is dated August 26, 2005; the notice letter attached to the Cobalt subpoena is dated October 14, 2005; and Plaintiffs produced documents attached as exhibits to the Pfizer and Bristol-Myers subpoenas by at least November 29, 2005. Thus, Plaintiffs have known about all of these entities for at least the past six months, although they have known about several of them for over a year. Yet, Plaintiffs intentionally waited until a month before the end of fact discovery to serve these third-party subpoenas.

This, of course, is not the first or only time that Plaintiffs have delayed seeking third-party discovery. On April 25, 2006, for example, Plaintiffs asked Defendants to consent to Plaintiffs' request for judicial assistance to obtain third-party discovery from a German company. Plaintiffs waited until two months before the close of discovery despite the fact that they indicated at the very beginning of this case that they anticipated needing third-party discovery. Indeed, Plaintiffs first raised the issue of possible foreign, third-party discovery during the parties original 26(f) conference. Thereafter, Defendants repeatedly stated that if Plaintiffs wanted such discovery that they should begin doing so immediately. Significantly, Judge Jordan also advised Plaintiffs on more than one occasion that they should immediately begin taking any such discovery that they believed was necessary. (*See, e.g.*, 12/20/05 Hearing Transcript at 10-11). Yet, Plaintiffs waited until near the end of discovery to begin the process of trying to obtain this information. And, yet again, Plaintiffs have no excuse for this delay.

Plaintiffs also have delayed producing relevant documents. For instance, Plaintiffs repeatedly have refused to make available 1,200 boxes of documents – documents purportedly related to Defendants' request for discovery on Plaintiffs' secondary considerations defense. Defendants have been asking for these documents for months. So far, Plaintiffs only have offered to discuss with Defendants where and under what conditions such documents might be made available for inspection. Additionally, Barr still awaits Plaintiffs' substantive response to the letter that that it sent early this month regarding the glaring deficiencies in Plaintiffs' privilege log. Further, Defendants deposed Bonnie Davis in early February 2006. Plaintiffs, however, produced many documents relevant to Dr. Davis well after her deposition, including documents produced in May. And, of course, Plaintiffs did not produce a witness on May 23 in response to Teva's 30(b)(6) deposition notice.

Given all of these facts (and we certainly could have included a longer list), Plaintiffs cannot credibly argue that they have reasonably cooperated in expediting this Hatch-Waxman litigation. Indeed, Plaintiffs' behavior is a classic example of the delay tactics that brand companies employ in Hatch-Waxman cases – cases where each day of delay is a victory for the brand company. And, to be clear, Defendants will object to any effort that Plaintiffs make to extend the discovery schedule in this case.

Moreover, your statement that Defendants have engaged in a strategy of "run[ning] out the clock" on discovery has no basis in fact. For example, while you once again complain about the dates that Defendants presented their 30(b)(6) witnesses for deposition, your letter (again) ignores, *inter alia*, the fact that Plaintiffs were offered, but rejected, earlier deposition dates for at least some witnesses. For example, Plaintiffs deposed third-party Cheryl Blume on May 10. But this is only after Plaintiffs rejected our offers of April 13 and May 2. You also complain that "Defendants" allegedly produced documents just before deposition. Not only do you fail to name any specific Defendant that purportedly did so, but you neglect to mention the fact that Plaintiffs produced documents just before the start of some depositions and, as discussed above, produced documents after a deposition already had taken place.

If Plaintiffs insist on continuing to send out letters that misstate the record, Defendants will have no choice but to waste time responding so that the record is clear. It is our hope, however, Plaintiffs will allow us to focus on addressing the substance of this case.

Very truly yours,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

AF

Christine J. Siwik

cc: Attached service list

SERVICE LIST

Via Facsimile and E-mail:

George F. Pappas *(gpappas@cov.com)* Roderick R. McKelvie *(mckelvie@cov.com)* Christopher N. Sipes *(csipes@cov.com)* Jeffrey B. Elikan *(jelikan@cov.com)* Laura H. McNeill *(lmcneill@cov.com)* **Kurt G. Calia** *(kcalia@cov.com)* **COVINGTON & BURLING** 1201 Pennsylvania Avenue, N.W. Washington, D.C. 20004-2401 Telephone: (202) 662-6000 Facsimile: (202) 662-6291	John G. Day *(jday@ashby-geddes.com)* **Steven J. Balick** *(sbalick@ashby-geddes.com)* **ASHBY & GEDDES** 222 Delaware Ave., 17th Fl. P.O. Box 1150 Wilmington, DE 19899 Telephone: (302) 654-1888 Facsimile: (302) 654-2067
Steven P. Berman *(sberman@corus.jnj.com)* Office of General Counsel **JOHNSON & JOHNSON** One Johnson & Johnson Plaza New Brunswick, NJ 08933 Telephone: (732) 524-2805 Facsimile: (732) 524-5866	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P. and Synaptech, Inc.	

Via E-mail:

Alan Bernstein *(abernstein@crbcp.com)* (x124) Mona Gupta *(mgupta@crbcp.com)* (x160) **CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.** 1635 Market Street, 11th Floor Philadelphia, PA 19103-2212 Telephone: (215) 567-2010 Facsimile: (215) 751-1142	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **RICHARDS, LAYTON & FINGER, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19801 Telephone: (302) 651-7509 Facsimile: (302) 651-7701
Counsel for Defendant Alphapharm Pty Ltd.	

Daniel F. Attridge, P.C. *(dattridge@kirkland.com)* Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson@kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **KIRKLAND & ELLIS LLP** 655 Fifteenth Street, N.W., Suite 1200 Washington, D.C. 20005-5793 Telephone: (202) 879-5000 Facsimile: (202) 879-5200	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* Adam W. Poff *(apoff@ycst.com)* **YOUNG CONAWAY STARGATT & TAYLOR LLP** The Brandywine Building 1000 West St., 17th Floor P.O. Box 391 Wilmington, DE 19899-0391 Telephone: (302) 571-6600 Facsimile: (302) 571-1253
Counsel for Defendants Teva Pharmaceuticals USA and Teva Pharmaceuticals Industries Ltd.	

Mary B. Matterer *(mmatterer@morrisjames.com)*
MORRIS JAMES HITCHENS & WILLIAMS LLP
222 Delaware Ave., 10th Floor
P.O. Box 2306
Wilmington, DE 19899-2306
Telephone: (302) 888-6800
Facsimile: (302) 571-1750

Counsel for Defendants Mylan Pharmaceuticals Inc. and Mylan Laboratories Inc.

George C. Lombardi *(glombardi@winston.com)*
Taras A. Gracey *(tgracey@winston.com)*
Lynn M. Ulrich *(lulrich@winston.com)*
Brian L. Franklin *(bfranklin@winston.com)*
WINSTON & STRAWN LLP
35 West Wacker Dr.
Chicago, IL 60601
Telephone: (312) 558-5000
Facsimile: (312) 558-5700

John C. Phillips, Jr. *(jcp@pgslaw.com)*
Brian E. Farnan *(bef@pgslaw.com)*
PHILLIPS, GOLDMAN & SPENCE, P.A.
1200 N. Broom St.
Wilmington, DE 19806
Telephone: (302) 655-4200
Facsimile: (302) 655-4210

Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.

EXHIBIT H

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202 662 6000
FAX 202 662 6291
WWW COV COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

KURT G. CALIA
TEL 202 662 5602
FAX 202 778 5602
KCALIA@COV.COM

June 15, 2006

VIA E-MAIL and FIRST CLASS MAIL

Amy D. Brody, Esq.
Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard Street, Suite 500
Chicago, IL 60610

Re: In re: '318 Patent Infringement Litigation; Civil Action No. 05-356-KAJ (consolidated)

Dear Amy:

This is in response to your June 12, 2006 letter concerning Plaintiffs' document production in this case. Your accusation that Plaintiffs have been "stalling" the inspection of the approximately 1,200 boxes of material that was first identified many months ago is disproved by the record, summarized below:

March 10, 2006 — Plaintiffs wrote to defendants' counsel about our February 13 teleconference, reiterating that Plaintiffs have approximately 1,200 boxes of marketing-related information. While we stated our belief that this information is not relevant to this case (a view reinforced by our production to date of thousands of pages of pertinent marketing-related information), we nevertheless indicated that we would be willing to permit inspection of the materials.

April 3, 2006 — We heard nothing for nearly a month until you wrote on April 3 to inquire about these documents (along with other document production issues). Your letter merely asked when you might inspect the documents; you did not explain the delay in responding to my March 10 letter.

April 5, 2006 — I promptly responded to your April 3 letter, suggesting that the parties conduct a teleconference to discuss how to conduct any inspection – which is necessary because the 1,200 boxes of materials contain some information that is privileged and/or patient sensitive, and because the materials are not all in the

same location. In my letter, I asked you when you would be available for such a discussion.

May 15, 2006 — I heard nothing from you for more than a month, until I received an email on May 15, when, ignoring my request for a teleconference, you asked where the documents are located and when defendants may inspect them. Your email did not acknowledge in any way the concerns set forth in my April 5 letter, nor did it explain why you had failed to respond to my April 5 letter for more than 5 weeks.

May 15, 2006 — I responded to your email approximately one hour later, reminding you of my April 5 suggestion for a conference call, and stating that we would be available to discuss the matter later that week (May 15 was a Monday). I further requested information from you about which of the defendants intended to inspect the documents, whether you hoped to inspect a multiple locations at once, when you hoped to begin, and how many people you anticipated would be involved.

May 31, 2006 — We received Christine Siwik's May 31, 2006 letter concerning a variety of discovery issues, in which she stated (falsely) that "Plaintiffs repeatedly have refused to make available 1,200 boxes of documents...." This letter did not respond to my May 15 email to you at all. The transparent purpose of Ms. Siwik's letter was to obfuscate defendants' dilatory conduct by mischaracterizing the documented history of discovery in this matter. Ms. Siwik's letter did not seek to facilitate the inspection of the documents nor did it seek a response from Plaintiffs about the inspection (or any other discovery issue).

June 12, 2006 — We responded to Ms. Siwik's May 31 letter, pointing out our repeated efforts to confer with you on an inspection of the documents, among other things, as proof of Plaintiffs' diligent discovery efforts.

June 12, 2006 — For the first time in a month (since May 15), you wrote about conducting an inspection. You again ignored our request (made months earlier) for a call to discuss the logistics of any inspection and our how the parties might address our concerns about privileged and/or patient-sensitive information in these documents. Instead, you asked for (a) an identification of

where the boxes are, and (b) the numbers of such boxes at each location and a description of their content so that you could advise us of your "proposed review" of these materials, suggesting that you are still considering whether to conduct an inspection.

* * *

Given the history set forth above, it is disingenuous for you to claim in your June 12 letter that "Plaintiffs are just stalling" as to these documents (or as to anything else in discovery, for that matter). How can you make such a statement in light of the delays caused by your unwillingness to place a simple phone call to discuss the inspection? We have met in person for depositions in this case on many occasions since my March 10 letter, and not once did you utter a word about any continuing desire to inspect documents, nor have you raised this issue in the literally dozens of telephone calls we have had in the last four months on various discovery matters. And I have heard nothing from the other defendants concerning a teleconference to discuss an inspection. In short, the clear history -- as set forth in the correspondence -- reveals that defendants have simply neglected to pursue this discovery offered by Plaintiffs over four months ago.

It is apparent that defendants are not interested in reviewing these documents, but instead wish to concoct a claim that Plaintiffs have somehow impeded defendants' discovery efforts for some other purpose. There simply is no other explanation for your refusal to make a simple phone call to coordinate on the inspection, which we invited you to do many months ago.

In any event, we respond to the two questions of your June 12 letter as follows:

(a) The approximately 1,350 boxes (it is more than the 1,200 initially estimated) are located in two locations -- about 150 of them are at a Janssen facility in Titusville, NJ, and about 1,200 of them are at an Iron Mountain storage facility in Somerset, NJ.

(b) As stated in prior correspondence, these documents relate to marketing of Razadyne®, and include information such as adverse event reports, case report forms, and raw clinical data. As we understand it, documents of these various types exist at both locations identified above.

We continue to believe that a conference call to discuss the mechanics of any inspection is required should defendants wish to inspect this material. Given the

volume and sensitivity of the material (and the sensitivity of the location of some of it at Janssen), defendants cannot simply show up, inspect the documents, and identify those to be photocopied. We will need to make arrangements as to the number of people to conduct the inspection, limits on access to these facilities (in terms of the number of days and time of day), pre-review by Plaintiffs so as to safeguard privileged and patient-sensitive information, and costs associated with photocopying, among other things.

We look forward to your response. Please do not hesitate to contact me if you have any questions.

Sincerely,



Kurt G. Calia

cc: All defense counsel (via email)
Steven Balick, Esq. (via email)

SERVICE LIST

By Electronic Mail and First Class Mail:	By Electronic Mail:
William A. Rakoczy *(wrakoczy@rmmslegal.com)* Christine J. Siwik *(csiwik@rmmslegal.com)* Amy D. Brody *(abrody@rmmslegal.com)* Lara Monroe-Sampson *(lmonroe-sampson@rmmslegal.com)* **Rakoczy, Molino, Mazzochi, Siwik LLP** 6 West Hubbard Street, Suite 500 Chicago, IL 60610 312.527.2157/phone; 312.527.4205/fax	Mary B. Matterer *(mmatterer@morrisjames.com)* **Morris James Hitchens & Williams LLP** 222 Delaware Avenue 10th Floor P.O. Box 2306 Wilmington, DE 19899-2306 302.888.6800/phone; 302.571.1750/fax
Counsel for Defendants Mylan Pharmaceuticals Inc. & Mylan Laboratories Inc.	

By Electronic Mail and First Class Mail:	By Electronic Mail:
Edward C. Donovan *(edonovan@kirkland.com)* Karen M. Robinson *(krobinson @kirkland.com)* Corey J. Manley *(cmanley@kirkland.com)* **Kirkland & Ellis LLP** 655 Fifteenth Street, NW Suite 1200 Washington, DC 20005-5793 202.879.5000/phone; 202.879.5200/fax	Josy W. Ingersoll *(jingersoll@ycst.com)* John W. Shaw *(jshaw@ycst.com)* **Young Conaway Stargatt & Taylor LLP** The Brandywine Building 1000 West Street 17th Floor Wilmington, DE 19899-0391 302.571.6600/phone; 302.571.1253/fax
Counsel for Defendants Teva Pharmaceuticals USA, Inc. & Teva Pharmaceuticals Industries Ltd.	

Taras A. Gracey *(tgracey@winston.com)* Lynn M. Ulrich *(lulrich @winston.com)* Brian L. Franklin *(bfranklin@winston.com)* **Winston & Strawn LLP** 35 West Wacker Drive Chicago, IL 60601 312.558.5600/phone; 312.558.5700/fax	
Counsel for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.	

Alan Bernstein *(abernstein@crbcp.com)* Mona Gupta *(mgupta@crbcp.com)* **Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.** 1635 Market Street, 11th floor Philadelphia, PA 19103-2212 215.567.2010/phone; 215.751.1142/fax	Frederick L. Cottrell, III *(cottrell@rlf.com)* Anne Shea Gaza *(gaza@rlf.com)* **Richards, Layton & Finger, P.A.** One Rodney Square P.O. Box 551 Wilmington, DE 19899 302.651.7700/phone; 302.651.7701/fax
Counsel for Defendant Alphapharm Pty Ltd.	

Steven J. Balick *(sbalick@ashby-geddes.com)* John G. Day *(jday@ashby-geddes.com)* **Ashby & Geddes** 222 Delaware Ave., 17th Floor P.O. Box 1150 Wilmington, DE 19899 302.654.1888/phone; 302.654.2067/fax	
Counsel for Plaintiffs Janssen Pharmaceutica N.V., Janssen, L.P., and Synaptech, Inc.	

EXHIBIT I

2.1

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

JANSSEN PHARMACEUTICA N.V., JANSSEN, L.P., and SYNAPTECH, INC.,	)	
Plaintiffs/Counterclaim-Defendants,	)	Civ. Action No. 05-371 (KAJ)
v.	)	
MYLAN PHARMACEUTICALS INC., and MYLAN LABORATORIES INC.,	)	
Defendants/Counterclaim-Plaintiffs.	)	

MYLAN PHARMACEUTICALS INC.'S AND MYLAN LABORATORIES INC.'S FIRST REQUEST FOR PRODUCTION OF DOCUMENTS TO JANSSEN PHARMACEUTICA N.V. (Nos. 1-22)

Defendants/Counterclaim-Plaintiffs Mylan Pharmaceuticals Inc. and Mylan Laboratories Inc. hereby request that Plaintiff/Counterclaim-Defendant Janssen Pharmaceutica N.V. produce the documents set forth below for inspection and copying at the offices of RAKOCZY MOLINO MAZZOCHI SIWIK LLP, 6 West Hubbard Street, Suite 500, Chicago, Illinois 60610, or at such other location as mutually agreed to by the parties, within thirty (30) days after the service of this Request, pursuant to Federal Rule of Civil Procedure 34 and D. Del. LR 26.1.

DEFINITIONS

1. "Mylan Pharmaceuticals" shall mean Mylan Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of West Virginia, and a named defendant to the Current Litigation.

2. "Mylan Laboratories" shall mean Mylan Laboratories Inc., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, and a named defendant to the Current Litigation.

3. "Mylan" means Mylan Pharmaceuticals and Mylan Laboratories collectively.

4. "Janssen" shall mean Janssen Pharmaceutica N.V., a named plaintiff to the Current Litigation, and, a corporation organized and existing under the laws of Belgium, and any of its present or former divisions, and shall also include any present or former parent, subsidiary, affiliated or related corporation or any other related entity of Janssen Pharmaceutica N.V., including Janssen, L.P. "Janssen" shall further mean all past or present directors, officers, employees, agents, representatives, or persons acting on behalf of any of the foregoing entities.

5. "Janssen, L.P." shall mean Janssen, L.P., a named plaintiff to the Current Litigation, and a corporation organized and existing under the laws of the State of New Jersey, and any of its present or former divisions, and shall also include any present or former parent, subsidiary, affiliated or related corporation or any other related entity of Janssen, L.P. "Janssen, L.P." shall further mean all past or present directors, officers, employees, agents, representatives, or persons acting on behalf of any of the foregoing entities.

6. "Synaptech" shall mean Synaptech, Inc., a named plaintiff to the Current Litigation, and a corporation organized and existing under the laws of the State of New York, and any of its present or former divisions, and shall also include any present or former parent, subsidiary, affiliated or related corporation or any other related entity of Synaptech, Inc. "Synaptech" shall further mean all past or present directors, officers, employees, agents, representatives, or persons acting on behalf of any of the foregoing entities.

7. "ANDA" shall mean an abbreviated new drug application as provided under 21 U.S.C. § 355(j), and the corresponding implementing regulations at 21 C.F.R. § 314 *et seq.*

8. "The '318 patent" shall mean U.S. Patent No. 4,663,318, issued on May 5, 1987.

9. "Current Litigation" shall mean the lawsuit entitled *Janssen Pharmaceutica N.V. et al. v. Mylan Pharmaceuticals Inc.*, Civil Action No. 05-371 (KAJ), pending in the United States District Court for the District of Delaware.

10. "Related Litigation" shall mean any lawsuit filed by Janssen, Janssen, L.P. and/or Synaptech wherein Janssen, Janssen, L.P. and/or Synaptech assert the '318 patent.

11. "Galantamine" shall mean the chemical compound (4a*S*,6*R*,8a*S*)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-*ef*][2]benzazepin-6-ol hydrobromide, which is the active pharmaceutical ingredient in pharmaceutical products approved by FDA for the treatment of mild to moderate dementia of the Alzheimer's type.

12. "PTO" shall mean the U.S. Patent and Trademark Office.

13. "FDA" shall mean the U.S. Food and Drug Administration.

14. The terms "you" and "your" mean Janssen and all related entities, as defined above.

15. The term "communication" means the transmittal of information (in the form of facts, ideas, inquiries or otherwise).

16. The term "document" or "documents" is used herein in a comprehensive sense as set forth in Rule 34(a) of the Federal Rules of Civil Procedure, and shall be defined to include, without limitation, all tangible things, all written, printed, typed, photocopies, photographic, graphic or recorded matter of any kind, any recorded material however produced or reproduced, including agreements, books, calendars, charts, contracts, communications, computer databases, computer memory media, computer printouts, correspondence, desk pads, diaries, drafts, drawings, entries in books of account, electronic mail, facsimile transmissions, files, folders,

graphs, guidelines, instructions, lists, manuals, memoranda, minutes, notes, operating procedures, pamphlets, reports, rules, studies, telegrams, teletypes, and all written or tangible things that can be derived from any computer database, microfilm, microfiche, or other storage medium. A draft or non-identical copy is a separate document within the meaning of this term.

17. The term "person" is defined as any natural person or any business, legal or governmental entity or association.

18. When referring to a person, "identify" means to give, to the extent known, the person's full name, present or last known address, and when referring to a natural person, additionally, the present or last known place of employment.

19. When referring to documents, "identify" means to give, to the extent known, the: (i) type of document; (ii) general subject matter; (iii) date of the document; and (iv) author(s), addressee(s), and recipient(s).

20. The term "concerning" means relating to, referring to, describing, evidencing, or constituting.

21. Something is "relating to" a subject if it makes a statement about, refers to, mentions, discusses, describes, reflects, deals with, consists of, constitutes, comprises, concerns, evidences, records, or in any way pertains to the subject, either in whole or in part, and either directly or indirectly.

22. The terms "all" and "each" shall be construed as all and each.

23. The connectives "and" and "or" shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside its scope.

24. The use of the singular form of any word includes the plural and vice versa.

25. The term "including" means without limitation.

INSTRUCTIONS

1. No request shall be construed with reference to any other request for purposes of limitation.

2. Each requested document shall be produced in its entirety, including all attachments and enclosures. If a portion of a document is responsive to a request, produce the entire document, including all attachments, enclosures, "post-it"-type notes, and any other matter physically attached to the document. If a document responsive to any request cannot be produced in full, it shall be produced to the extent possible with an explanation stating why production of the remainder is not possible.

3. If a document responsive to any request is no longer in your possession, custody, or control, state: (i) its date; (ii) author(s); (iii) recipient(s); (iv) subject matter; (v) when such document was most recently in your possession, custody, or control; (vi) what disposition was made of the document; and, (vii) the person or entity, if any, now in possession, custody, or control of the document. If a document has been destroyed, identify: (i) the date of destruction; (ii) the person who destroyed the document(s); (iii) the person who directed the document to be destroyed; and, (iv) the reason(s) for its destruction.

4. All documents produced in response to these requests shall be produced in the same order as they are kept in the ordinary course of business and, where attached, shall not be separated or disassembled. If documents responsive to any request are normally kept in a file or folder, also produce that file or folder with any labels attached thereto, and indicate the company, division, department, and/or individual from whose files the document is being produced. If responsive documents are segregated or separated from other documents, whether by inclusion in

binders, files, sub-files, or by use of dividers, tabs or any other method, produce such documents in that form.

5. If, in responding to these document requests, you claim any ambiguity in interpreting either a request or a definition or instruction applicable thereto, such claim shall not be utilized by you as a basis for refusing to respond, but you shall set forth as part of your response to the request the language deemed to be ambiguous and the interpretation chosen to be used in responding to the request.

6. If, in responding to these document requests, you assert a privilege to any particular request, you must identify the nature of the privilege (including work product) that is being claimed, and, if the privilege is governed by state law, indicate the state's privilege rule being invoked. In addition, the following information shall be provided in the objection:

a. For documents: (i) the type of document; (ii) the general subject matter of the document; (iii) the date of the document; and (iv) such other information as is sufficient to identify the document for a subpoena duces tecum, including, where appropriate, the author of the document, the addressees of the document, and any other recipients shown in the document, and, where not apparent, the relationship of the author, addressees, and recipients to each other;

b. For oral communications: (i) the name of the person making the communication and the names of persons present while the communication was made and, where not apparent, the relationship of the persons present to the person making the communication; (ii) the date and place of communication; and (iii) the general subject matter of the communication.

7. Each request for documents is continuing in nature. If, after responding to these requests, you obtain or become aware of further documents responsive to any request, such documents shall be produced promptly in accordance with Rule 26(e) of the Federal Rules of Civil Procedure and the definitions and instructions herein.

DOCUMENT REQUESTS

1. All documents, communications and things on which Janssen intends to rely at trial in connection with any of the allegations in the complaint filed in the Current Litigation.

2. All documents, communications, and things referred to, relied upon, cited, or otherwise used to prepare any answer to any interrogatory or request to admit propounded by Mylan in the Current Litigation.

3. All documents, communications, and things referred to or relied upon by Janssen in asserting any and all allegations in the complaint filed in the Current Litigation.

4. All documents surrounding the alleged invention of the '318 patent, including but not limited to:

(a) all laboratory notebooks or other documents relating to or concerning the conception and/or reduction to practice of the alleged invention of the '318 patent;

(b) documents relating to the identity of the individuals who allegedly conceived of, and/or reduced to practice or assisted in the reduction to practice of, the invention claimed;

(c) documents relating to the date(s) on which such alleged conception and/or reduction to practice occurred;

(d) all inventor disclosure statements that were prepared;

(e) all documents relating to the decision to file and prosecute the '318 patent; and

(f) all documents and/or information that the named inventor of the '318 patent, including her representatives, considered in connection with the development of the invention allegedly disclosed in the '318 patent, and/or in connection with the prosecution of this patent, regardless of whether such documents or information was cited to the PTO.

5. All licenses or other agreements, assignments, transfers or liens concerning the '318 patent.

6. All documents supporting any assertions of secondary considerations of non-obviousness that Janssen intends to raise in the Current Litigation and/or in any Related

Litigation, including but not limited to, proof of nexus, profit margins, and marketing expenditures.

7. All documents that Janssen contends show the commercial success of any Janssen galantamine product.

8. All documents concerning or referring to competition for the sale of any Janssen galantamine product.

9. All notes, memoranda, and other written records of communications (*including* "call notes") between Janssen and/or its agents and any managed care organization, pharmacy benefit manager, physician, nurse, pharmacist, and/or other medical or medical office personnel concerning, referring to or relating to any galantamine product (including any Janssen galantamine product).

10. All documents and things concerning, referring to or relating to the market for drugs used for the treatment of mild to moderate dementia of the Alzheimer's type, including, but not limited to, documents identifying all drugs used for the treatment of mild to moderate dementia of the Alzheimer's type.

11. All documents and things concerning, referring to or relating to data and/or other information showing the uses for which any galantamine product (including Janssen's galantamine product) is prescribed, used, and/or taken, including, but not limited to National Drug and Therapeutic Index data for any galantamine product.

12. All documents and things concerning, referring to or relating to the marketing of any galantamine product (including any Janssen galantamine product), including, but not limited to:

(a) all manuals, presentations, and/or other materials provided to, and/or used to train, sales representatives;

(b) all market research materials (including but not limited to surveys conducted by or on behalf of Janssen, scripts used, and results obtained);

(c) all communications between or among any persons at Janssen's corporate headquarters, persons in district or regional management, and sales representatives;

(d) all notes, handouts, slides, and other presentation materials used at any plan of action (POA), launch, and/or other meeting;

(e) all marketing plans and product forecasts; and

(f) all field bulletins from Janssen to its sale representatives.

13. All marketing and/or sales materials concerning, referring to or relating to any product used for the treatment of mild to moderate dementia of the Alzheimer's type (including any Janssen galantamine product), including, but not limited to:

(a) all display booth panels;

(b) all detail pieces or aids used by and/or provided to sales representatives, including but not limited to, ad slicks, slim jims, flash cards, and shelf-talkers;

(c) all telemarketing scripts, tele-detailing scripts, selling scripts, detailing scripts and/or verbatims used by and/or provided to sales representatives;

(d) all materials provided to physicians, managed care organizations, pharmacy benefit managers, pharmacists, and/or consumers;

(e) all advertisements appearing in journals, magazines, and/or newspapers;

(f) all patient education materials; and

(g) all copies of articles published by third-parties (sometimes referred to as reprints) used by and/or provided to sales representatives.

14. All agreements concerning the rights to market and/or sell galantamine in the United States.

15. All documents and things concerning, referring to or relating to data and/or other information showing sales of and/or prescriptions for any galantamine product (including Janssen's galantamine product), including, but not limited to:

(a) National Drug and Therapeutic Index (NDTI) data;

(b) Xponent data and/or Xponent PlanTrak data;

(c) Formulary Focus data;

(d) IMS data;

(e) Scott-Levin data;

(f) Calls, Samples, and Details data;

(g) Integrated Promotional Services (IPS) data; and

(h) Early View data.

16. All documents that Janssen has produced or provided to any party, expert, consultant, or any other third-party, relating to or concerning the Current Litigation and/or any Related Litigation concerning galantamine.

17. All documents that any party, expert, consultant, or any other third-party has drafted or otherwise prepared on behalf of Janssen and/or Janssen's attorneys and/or agents (including all drafts) relating to or concerning the Current Litigation, any Related Litigation and any other U.S. or foreign litigation relating to or concerning galantamine.

18. Any and all communications between or among Janssen, Janssen, L.P. and/or Synaptech relating to or concerning:

(a) the '318 patent;

(b) the Current Litigation;

(c) any Related Litigation;

(d) the alleged invention of the '318 patent;

(e) the prosecution of the '318 patent;

(f) any ANDA referencing NDA No. 21-169; and

(g) any notification received under 21 U.S.C. § 355(j) referencing NDA No. 21-169.

19. Any and all notifications received under 21 U.S.C. § 355(j) referencing NDA No. 21-169 and all documents relating to or concerning all such notifications.

20. Any and all English language translations of any foreign-language documents requested in Mylan's document production requests.

21. All documents concerning any of Janssen's policies and procedures for making, distributing, storing, retaining and/or destroying documents and records.

22. All documents and things depicting or otherwise evidencing Janssen's organizational structure as a company (*e.g.*, organizational charts), from at least January 1, 1980 to the present.

Dated: September 12, 2005.

By: _____

Mary B. Matterer # 2696
MORRIS, JAMES, HITCHENS & WILLIAMS LLP
222 Delaware Ave., 10th Floor
Wilmington, DE 19801
Telephone: (302) 888-6800
Facsimile: (302) 571-1750
mmatterer@morrisjames.com

Of Counsel (admitted pro hac vice):
William A. Rakoczy
Christine J. Siwik
Amy D. Brody
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
6 West Hubbard Street, Suite 500
Chicago, IL 60610
Telehone: (312) 527-2157
Facsimile: (312) 222-6321
wrakoczy@rmmslegal.com

Attorneys for Defendants/Counterclaim-Plaintiffs
Mylan Pharmaceuticals Inc. and Mylan Laboratories Inc.